Newsletter

Int. Rev. Allergol. Clin. Immunol. Family Med., 2014, XX/1: 023-027 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2014, XX/1: 023-027

Title: Indacaterol in the control of airflow obstruction in patients with COPD – preliminary report

/ Authors: Płusa T., Omernik A., Chudzicka A.

More details

04-01-2014

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Indacaterol in the control of airflow obstruction in patients with COPD – preliminary report

Płusa T., Omernik A., Chudzicka A.


Military Institute of Medicine in Warsaw, Poland, Central Clinical Hospital of the Ministry of National Defense, Department of Internal Medicine, Pneumonology and Allergology

Int. Rev. Allergol. Clin. Immunol. Family Med., 2014; Vol. 20, No. 1, 023

Indacaterol is a long-acting agonist of β2-adrenergic receptor whose clinical effect starts 5 minutes after inhalation and lasts more than 24 hours.
The aim
of the study was to carry out a preliminary assessment of the speed and duration of indacaterol action in patients with COPD, as part of ongoing research on the importance of small airways in obstructive diseases of the respiratory tract.
Materials and methods
. The study involved 12 patients (8 men and 4 women) aged 51–64 years (mean 57.4), who were diagnosed with stage III COPD (FEV1 less than 50% predicted values) on the basis of GOLD guidelines. The mean treatment duration in observed patients was 10 years from diagnosis. After performing standard spirometry patient inhaled 300 μg of indacaterol (Onbrez, Novartis). Subsequent studies were performed at 1, 4, 8, 12 and 24 hours following basic parameters monitoring breathing. In the analysis, the percentage of the standard value of FVC (forced vital capacity), FEV1 (forced expiratory volume in one second) and the parameters to illustrate the efficiency of the flow through the respiratory tract, ie, MEF75,50,25 (maximal expiratory flow) – the maximum expiratory flow at selected moments of forced expiration.
Results
. It was found in the COPD patients 1 hour after indacaterol inhalation that values of FVC were increased by 5.70% (p
Conclusions. The study confirmed the rapid effect of indacaterol in patients with COPD. FEV1 significant increase persisted after a single dose of inhaled drug for 24 hours. In turn, an increase in the value of expiratory flows generated by inhalation indicates a real opportunity to control the changes in the most peripheral parts of the bronchial tree.

Key words: indacaterol, COPD, spirometry